French biowearable startup Metyos raises €2.3M in pre-Seed funding: Know more

Paris-based Metyos, a medtech startup tackling chronic kidney disease (CKD), announced that it has secured €2.3M in a pre-seed round of funding. 

The investment was led by Cenitz with participation from KIMA Ventures, Advans Lab, and Bpifrance, along with support from doctors, health insurance angels, and business leaders from Implicity, Deepmind, and Nabla.

Frederic Picq, the co-founder at Cenitz, says, “Our investment in Metyos was driven by its impressive founding team, a clear and growing market need, and the life-changing potential of its technology.”

“Alex and Olga bring a blend of entrepreneurial spirit and technical expertise that is rare and invaluable in the medtech space. Their track record and passion for healthcare innovation are evident in the strides Metyos has already made.”

“We see significant opportunity in Metyos not just because of its groundbreaking approach to CKD management, but because it represents the future of healthcare – a future where technology and the human experience come together to offer better, proactive care for all,” adds Picq.

A medical device startup working on connected wearable biosensors

Metyos aims to transform chronic kidney disease (CKD) management with its biowearable sensor and platform, providing real-time biomarker readings for doctors to monitor kidney function and empower patients in self-care. 

With CKD affecting 10 per cent of the population and being a major cause of death, Metyos seeks to proactively manage symptoms and slow disease progression, benefiting both patients and healthcare systems.

Metyos, founded by CEO Alexandre Boulanger and CTO Olga Chashchina, aims to transform the lives of over 800 million CKD patients globally.

The company is driven by its founders: CEO Alexandre Boulanger and CTO Olga Chashchina. Boulanger, a serial medtech entrepreneur, previously founded and scaled Wandercraft, known for pioneering FDA-cleared and CE-marked lower limb exoskeleton technology. 

Dr. Chashchina, with a PhD in biomedical engineering and business acumen from McKinsey and an MBA, brings expertise in biosensors to the team.

Capital utilisation

The funding secured by Metyos will be allocated towards advancing its wearable technology, with a focus on progressing through clinical trials in preparation for FDA clearance.

Currently, the company is actively recruiting participants for clinical trials to enhance and validate its biowearable technology.

Co-founder Boulanger says, “Our mission at Metyos is to move healthcare away from reactive care towards proactive disease management.”

“A healthcare future where millions of CKD patients are empowered to take control of their health, and where they can access life-saving early detection and personalised interventions.”

“This funding, and the support and belief of the brilliant investors it brings with it, will help make this future a reality and help change the lives of so many patients and medical professionals worldwide.”